Drug intelligence / Profile preview

AdCh63-MSP1 + MVA-MSP1

Development stage: Unknown
Lead developer: University of Oxford
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A heterologous prime-boost malaria vaccine regimen targeting the blood-stage Plasmodium falciparum parasite. It consists of a chimpanzee adenovirus vector (AdCh63/ChAd63) expressing MSP1 for priming, followed by a modified vaccinia virus Ankara (MVA) vector expressing the same MSP1 antigen for boosting. The MSP1 antigen is designed with conserved blocks of sequence and two divergent allelic sequences to address antigenic polymorphism and induce strain-transcending immunity.

Other names: AdCh63 MSP1 + MVA MSP1-University of Oxford-malariaChAd63 MSP1 + MVA MSP1AdCh63-MSP1/MVA-MSP1

Targets

MSP1 (Merozoite surface protein 1)

Beyond the preview

Go deeper on AdCh63-MSP1 + MVA-MSP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdCh63-MSP1 + MVA-MSP1.

Explore the full profile